Acid-suppressing Drugs Pregnancy Asthma Offspring Study

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Asthma in Offspring

Treatments

Drug: Risk of asthma in offspring

Study type

Observational

Funder types

Industry

Identifiers

NCT01787435
D9612N00018

Details and patient eligibility

About

The purpose of this study is 1. To estimate the association between prenatal exposure to proton pump inhibitors (PPIs) and the risk of asthma during childhood. 2. To estimate the association between prenatal exposure to H2-receptor antagonists (H2RAs) and the risk of asthma during childhood.

Full description

A cohort study on the association between acid-suppressing drugs in pregnancy and asthma in the offspring

Enrollment

10,116 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Females aged 18-45 years with at least one pregnancy between 1 January 1995 - 31 December 2010 (see study population description)

Exclusion criteria

  • Males, females below age 18 and 45 years and above (see study population description)

Trial design

10,116 participants in 3 patient groups

All women exposed to PPI at any time during pregnancy
Description:
Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date
Treatment:
Drug: Risk of asthma in offspring
All women exposed to H2RA at any time during pregnancy
Description:
Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date
Treatment:
Drug: Risk of asthma in offspring
Pregnant women with no recorded use of acid suppressing drugs
Description:
Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems